Chemotherapy-Induced Amenorrhea - An Update.

Area of Science:

• Oncology
• Reproductive Endocrinology

Background:

• Chemotherapy-induced amenorrhea (CIA) definitions are inconsistent, leading to varied research findings on its incidence and contributing factors.
• The pathogenesis of CIA involves a reduction in ovarian reserves, impacting fertility and quality of life.
• Early menopause resulting from CIA can significantly affect patients' well-being and treatment options.

Purpose of the Study:

• To address the heterogeneity in CIA definitions and their impact on reported outcomes.
• To explore the relationship between specific chemotherapies and CIA occurrence.
• To highlight the importance of identifying preventive measures for CIA and its associated early menopause.

Main Methods:

• Review of literature examining the incidence and influencing factors of chemotherapy-induced amenorrhea.
• Analysis of diagnostic approaches, including sonographic and biochemical markers, for CIA.
• Discussion of the implications of CIA for endocrine therapy choices (e.g., tamoxifen vs. aromatase inhibitors).

Main Results:

• Significant variability in CIA incidence is observed, dependent on the specific chemotherapy regimen used.
• Ovarian reserve reduction is a key factor in CIA development.
• CIA and subsequent early menopause can lead to reduced quality of life and infertility, but may also have positive prognostic significance.

Conclusions:

• Standardizing CIA definitions is essential for consistent research and clinical practice.
• Monitoring ovarian reserve and utilizing diagnostic tools can aid in managing CIA.
• Preventive strategies, such as GnRH analogues, are important for mitigating the adverse effects of CIA and preserving fertility.